Claims

1. Use of an extracellular matrix modulating agent in the manufacture of a medicament for the treatment of Fuchs endothelial corneal dystrophy FECD by modulating the expression of extracellular matrix by corneal endothelial cells, wherein the agent comprises 1-(4-fluoro-5-iso quinolinesulfonyl)-2-methyl-1,4- homopiperazine or a salt thereof, or a solvate thereof.

2. The use according to claim 1, wherein the 1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine is (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine.

3. The use according to claim 1 or claim 2, wherein the medicament is to prevent and/or suppress the guttae formation.

4. The use according to claim 1 or claim 2, wherein the medicament is to prevent and/or suppress the recurrence of the guttae formation.

5. The use according to any one of claims 1 to 4, wherein the medicament is a liquid formulation.

6. An extracellular matrix modulating agent for use in the treatment of a corneal disorder, by modulating the expression of extracellular matrix by corneal endothelial cells comprising 1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof.